Glenmark Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Glenmark Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1678.9, up 2.5% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.11% on the day, quoting at 24726.7. The Sensex is at 80745.92, down 0.07%. Glenmark Pharmaceuticals Ltd has risen around 17.43% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 9.31% in last one month and is currently quoting at 22374.25, up 0.85% on the day. The volume in the stock stood at 7.48 lakh shares today, compared to the daily average of 10.77 lakh shares in last one month.

The benchmark August futures contract for the stock is quoting at Rs 1675.75, up 2.33% on the day. Glenmark Pharmaceuticals Ltd is up 121.2% in last one year as compared to a 27.48% spurt in NIFTY and a 47.45% spurt in the Nifty Pharma index.

The PE of the stock is 28.57 based on TTM earnings ending June 24.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 1633.65, up 4.33% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 24574.45. The Sensex is at 80465.57, up 0.04%. Glenmark Pharmaceuticals Ltd has added around 14.27% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 7.84% in last one month and is currently quoting at 22106.5, up 0.69% on the day. The volume in the stock stood at 17.75 lakh shares today, compared to the daily average of 10.07 lakh shares in last one month.

The benchmark August futures contract for the stock is quoting at Rs 1630.45, up 3.94% on the day. Glenmark Pharmaceuticals Ltd is up 110.78% in last one year as compared to a 26.71% gain in NIFTY and a 45.17% gain in the Nifty Pharma index.

The PE of the stock is 30.99 based on TTM earnings ending March 24.

Powered by Capital Market - Live News

The solution is the generic version of 'Pataday Twice Daily Relief’, which is distributed by Alcon Laboratories, Inc. The registered trademark ‘Pataday’ is owned by Novartis AG.

Olopatadine belongs to a group of medicines called antihistamines. It is used to treat seasonal allergic conjunctivitis (infection, itching, redness, and swelling of the eye) caused due to pollens, dust, animal fur, and other allergens.

According to Nielsen, syndicated data for the latest 52 weeks’ period ending 13 July 2024, the ‘Pataday Twice Daily Relief’ (OTC) market achieved annual sales of approximately $26.4 million.

Fabio Moreno, Head – OTC sales & marketing, Glenmark Pharmaceuticals Inc. said, “We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers.”

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses.

The drug maker reported consolidated net profit of Rs 340.27 crore in Q1 FY25, significantly higher from Rs 14.48 crore in Q1 FY24. Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024.

Powered by Capital Market - Live News